HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH, a drug delivery company focusing on the topical application of ophthalmic technologies for poorly soluble drugs, today announced that its observational study NT-001, which placed NovaTears® OTC eye drops in 30 patients with symptoms of mild to moderate evaporative dry eye disease, successfully demonstrated effectiveness and safety in relief of dry eye symptoms.
The primary objective of the open, prospective, uncontrolled post-market clinical follow-up study (treatment survey) was to confirm whether NovaTears® was able to successfully lubricate the ocular surface, stabilize the eye’s tear film, and relieve adverse symptoms associated with dry eye disease. Additionally, local tolerability and safety of NovaTears® was assessed when used in accordance with its approved labeling.
Help employers find you! Check out all the jobs and post your resume.
